News
News
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the …
NHRI Enters Technology Transfer Agreement of T-1501 (DBPR186) with Taivex Therapeutics Corp.
National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, T-1501, with global patents. About DBPR186Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. T-1501 is a developmental drug candidate for …
Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June 28 and received approval on August 20. The anticipated initiation of the Phase I trial remains by end of 2021. T-1301 Phase I trial is a multi-centered study in Taiwan. The oral solid dosage form …
Announces the Initiation of Phase I Clinical Trial of T-1201, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in …
